Despite the well-established efficacy of anti-angiogenic drugs in the treatment of advanced solid cancers, inhibitors of the VEGF/VEGFR pathway have consistently produced disappointing clinical outcomes in certain types of tumors, including breast cancer [4, 19]. This evidence concerns the gene KDR and breast carcinoma.